ArticleWorld journal of gastroenterology2025
Insights into the GALAD score: A new optimal cut-off for hepatocellular carcinoma.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Refining early detection of hepatocellular carcinoma: The promise of the GALAD score.World journal of gastroenterology · 2026Article
- Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic liver disease (CLD) causes approximately two million deaths each year, and its clinical diagnosis and management remain challenging. Ultrasound is currently the most widely used technique for disease detection.
aimTo propose a practical cut-off value for identifying patients with hepatocellular carcinoma (HCC) among those with compensated advanced CLD or healthy individuals using the GALAD score, an algorithm based on a formula that incorporates gender, age, serum alpha-fetoprotein (AFP), AFP-L3, and des-gamma-carboxy prothrombin values.
methodsThis cross-sectional analysis was conducted using prospectively collected data from five cohorts (
resultsUsing healthy subjects as reference, a GALAD score cut-off of -1.67 identified HCC with a sensitivity of 89.77% and specificity of 97.59%. Individuals with GALAD values > -1.67 exhibited a moderate to very high probability (over 90%) of having HCC. When cirrhotic patients were used as the reference category, a cut-off of -0.77 yielded a sensitivity of 78.17% and a specificity of 89.55%.
conclusionWe strongly recommend incorporating this GALAD cut-off into clinical guidelines for the screening of patients with a compensated advanced CLD who are at high risk of developing HCC. Given the rapid global rise in metabolic-associated steatotic liver disease (MASLD)-related CLD, future research should prioritize larger MASLD cohorts to establish the most appropriate GALAD cut-off for diagnostic use, compared to healthy controls and to patients with other forms of CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.